Research Article
Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries
Table 3
Estimated prevalence of post-MI patients eligible to PCSK9 inhibitors according to the EAS/ESC and AIFA criteria.
| ||||||||||||||||||||||||||||||
DM, diabetes mellitus; eCrCl, estimated creatinine clearance, LDL-C, low density lipoprotein cholesterol.†These groups included patients receiving any statins at any dosage. Monoterapy with ezetimibe has been taken as a proxy of statin intolerance.‡High intensity statins have been considered atorvastatin 40–80 mg /day or rosuvastatin 20–40 mg/day. Monoterapy with ezetimibe has been taken as a proxy of statin intolerance. |